 Allogene Therapeutics Inc. ALLO, 1.71 shares were halted in the extended session Thursday after the biotech drug developer said the Food and Drug Administration placed a hold on the companys cancer drug clinical trials. Allogene shares closed up 1.7 at 24.38 in the regular session. 